The European journal of health economics : HEPAC : health economics in prevention and care
Total costs of different lines of treatment in diffuse large B-cell lymphoma in Denmark - a real-world data analysis.
Christian Graves Beck, Martin Lucas Jørgensen, Maya Friis Kjaergaard, Søren Ramme Bro, Tove Holm-Larsen
Published: 202510.1007/s10198-025-01843-x
Abstract
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Cure rate is high after first-line treatment, however, prognosis for relapse/refractory patients remains poor. Multiple treatments to DLBCL have recent…
Preview only. Read the full abstract at the source